Abstract
In this issue of Blood, Nieborowska-Skorska et al show that exposure of myeloproliferative neoplasm (MPN) cells to the JAK inhibitor, ruxolitinib, results in blockage of DNA damage repair pathways, thereby exacerbating double-strand DNA breaks and creating a synthetic lethal susceptibility to poly-ADP-ribose polymerase (PARP) inhibitors. Consequently, the combination of ruxolitinib with PARP inhibitors leads to elimination of quiescent and proliferating MPN leukemic stem/progenitor cells in vitro and in mouse models.
Original language | English (US) |
---|---|
Pages (from-to) | 2814-2816 |
Number of pages | 3 |
Journal | Blood |
Volume | 130 |
Issue number | 26 |
DOIs | |
State | Published - Dec 28 2017 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology